Publication date: Aug 27, 2024

COVID-19 vaccine efficacy has been evaluated in controlled clinical trials and serves as a benchmark for evaluating the protection acquired from prior COVID-19 infection (“natural immunity”). A cohort of persons with a prior COVID-19 infection was matched to a cohort of COVID-19 vaccinated persons and the risk of reinfection post-COVID-19 infection was compared to the risk of a COVID-19 infection post-vaccination. The hazard ratio (HR) for risk of reinfection from day 90 to 300 after initial COVID-19 infection vs. vaccine breakthrough infection was 0. 48, 95% Confidence Interval (CI) 0. 31-0. 73). Thus from 90 to 300 days after COVID-19 infection, the post-COVID-19 infection cohort had a lower risk of COVID-19 infection compared with those fully vaccinated. The risk of death associated with the initial COVID-19 infection requisite for acquiring post-COVID-19 immunity was also assessed. The hazard ratio (HR) for deaths from all causes among those acquiring immunity via COVID-19 infection vs. vaccination was 14. 9 (95% CI 7. 27-30. 4). Thus, while post-COVID-19 immunity was on a level comparable to that of vaccination, there was a 15-fold higher mortality resulting from achieving “natural immunity” versus acquiring vaccine-provided immunity.

Semantics

Original Article